Tzield (teplizumab-mzwv)

Tzield is a CD3-antibody approved to delay the onset of Stage 3 type 1 diabetes in people over the age of 8. The medication is given to people with stage 2 type 1 diabetes, meaning they have two or more pancreatic islet autoantibodies damaging the pancreatic beta cells that make insulin, leading to disrupted glucose control. Tzield is given via infusion daily over 14 consecutive days. After infusion, Teplizumab-mzwv binds to certain immune system cells and is thought to work by stopping the immune system attack on the insulin-producing beta cells in the pancreas.